U.S. Stock Market Moves: Eli Lilly Soars on October 22—Positive Phase 3 Results for OSA and Drug Development

Eli Lilly's Surge on October 22: Analysis

Keywords: Positive OSA Phase III trials, Drug development

1. On October 22, The New England Journal of Medicine published results from two Phase III studies of Eli Lilly’s investigational drug retatrutide for the treatment of obstructive sleep apnea: a total of 691 moderate to severe patients were enrolled. The studies showed that, regardless of whether patients had type 2 diabetes, retatrutide significantly reduced the apnea-hypopnea index, improved sleep breathing, and led to weight loss.

2. On October 19, Eli Lilly announced that the Phase III SHINE-2 study of Omvoh for treating pediatric ulcerative colitis met its primary endpoint; among 52 clinical responders aged 6 to 17, 50% achieved clinical remission at week 52. The company plans to submit the study results to global regulatory authorities in a bid to expand the drug’s indications.

(Disclaimer: This content is compiled using AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)